You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Muscarinic receptor agonist that displays roughly equal affinity at all receptor subtypes (Ki values are 2.3, 2.4, 3.6, 3.8 and 4.3 μM for hM1, hM2, hM3, hM4 and hM5 receptors respectively). Cognitive enhancer; reverses spatial memory deficits in rats.
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 190.67. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||5.24 mL||26.22 mL||52.45 mL|
|5 mM||1.05 mL||5.24 mL||10.49 mL|
|10 mM||0.52 mL||2.62 mL||5.24 mL|
|50 mM||0.1 mL||0.52 mL||1.05 mL|
References are publications that support the biological activity of the product.
Sedman et al (1995) Preclinical and phase I clinical characterization of CI-979/RU35926, a novel muscarinic agonist for the treatment of Alzheimer's disease. Life Sci. 56 877 PMID: 10188788
Wood et al (1999) Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry. Br.J.Pharmacol. 126 1620 PMID: 10323594
Schwarz et al (1999) Milameline (CI-979/RU35926): a muscarinic receptor agonist with cognition-activating properties: biochemical and in vivo characterization. J.Pharmacol.Exp.Ther. 291 812 PMID: 10525104
If you know of a relevant reference for Milameline hydrochloride, please let us know.
View Related Products by Product Action
Keywords: Milameline hydrochloride, Milameline hydrochloride supplier, Muscarinic, receptors, agonists, Acetylcholine, ACh, Non-selective, Muscarinics, 2604, Tocris Bioscience
Citations for Milameline hydrochloride
Citations are publications that use Tocris products.
Currently there are no citations for Milameline hydrochloride. Do you know of a great paper that uses Milameline hydrochloride from Tocris? Please let us know.
Reviews for Milameline hydrochloride
There are currently no reviews for this product. Be the first to review Milameline hydrochloride and earn rewards!
Have you used Milameline hydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.